Enanta Pharmaceuticals | ENTA - Debt


Enanta Pharmaceuticals reported $1.35M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 983.69M 5.77M Jun/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 8.09B 1.53B Jun/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Gilead Sciences USD 22.17B 2.76B Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Immunic USD 0 0 Jun/2024
Incyte USD 38.27M 1.16M Jun/2026
Insmed USD 725.8M 1.82M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
J&J USD 49.04B 5.95B Jun/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 451.98M 486K Mar/2026
Merck USD 49.12B 222M Mar/2026
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 63.19B 536M Jun/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026